

1 **The GluA1 cytoplasmic tail regulates intracellular AMPA receptor trafficking and synaptic**
2 **transmission onto dentate gyrus GABAergic interneurons, gating response to novelty**

3
4 Gerardo Leana-Sandoval^{1,2}, Ananth V. Kolli^{1,2}, Carlene A. Chinn^{2,3}, Alexis Madrid^{1,2}, Iris Lo⁴, Matthew A.
5 Sandoval^{1,2}, Vanessa Alizo Vera^{2,3}, Jeffrey Simms⁴, Marcelo A. Wood^{2,3}, Javier Diaz-Alonso^{1,2}.

6
7 ¹ Department of Anatomy & Neurobiology, University of California at Irvine, CA, 92697, USA.

8 ² Center for the Neurobiology of Learning and Memory, University of California at Irvine, CA, USA.

9 ³ Department of Neurobiology & Behavior, University of California at Irvine, CA, 92697, USA.

10 ⁴ Gladstone Institute of Neurological Disease, San Francisco, CA 94158, USA.

11 * Correspondence to Javier Díaz-Alonso (j.diazalo@uci.edu).

12

13 **Abstract**

14 The GluA1 subunit, encoded by the putative schizophrenia-associated gene GRIA1, is required
15 for activity-regulated AMPA receptor (AMPA) trafficking, and plays a key role in cognitive and
16 affective function. The cytoplasmic, carboxy-terminal domain (CTD) is the most divergent region across
17 AMPAR subunits. The GluA1 CTD has received considerable attention for its role during long-term
18 potentiation (LTP) at CA1 pyramidal neuron synapses. However, its function at other synapses and,
19 more broadly, its contribution to different GluA1-dependent processes, is poorly understood. Here, we
20 used mice with a constitutive truncation of the GluA1 CTD to dissect its role regulating AMPAR
21 localization and function as well as its contribution to cognitive and affective processes. We found that
22 GluA1 CTD truncation affected AMPAR subunit levels and intracellular trafficking. Δ CTD GluA1 mice
23 exhibited no memory deficits, but presented exacerbated novelty-induced hyperlocomotion and
24 dentate gyrus granule cell (DG GC) hyperactivity, among other behavioral alterations. Mechanistically,
25 we found that AMPAR EPSCs onto DG GABAergic interneurons were significantly reduced, presumably
26 underlying, at least in part, the observed changes in neuronal activity and behavior. In summary, this
27 study dissociates CTD-dependent from CTD-independent GluA1 functions, unveiling the GluA1 CTD as
28 a crucial hub regulating AMPAR function in a cell type-specific manner.

29

30 **Keywords:** AMPA receptor, GluA1, C-tail, Carboxy-terminal domain, schizophrenia, dentate gyrus,
31 novelty response, LTP, intracellular trafficking, PV+ interneuron.

32

33 Introduction

34 AMPA receptors (AMPA) mediate moment-to-moment excitatory synaptic transmission at
35 synapses throughout the CNS. Additionally, specific and sustained increases in the postsynaptic
36 AMPAR complement underlie long-term potentiation (LTP) (Kauer, Malenka et al. 1988, Muller, Joly et
37 al. 1988), which plays a crucial role in forms of learning and memory (Martin, Grimwood et al. 2000,
38 Nicoll 2017, Gall, Le et al. 2024). AMPARs assemble into heterotetramers of pore-forming subunits
39 (GluA1-4), decorated by auxiliary subunits. Subunit composition imparts AMPARs' biophysical
40 properties and trafficking behavior (Malinow and Malenka 2002, Collingridge, Isaac et al. 2004, Diering
41 and Huganir 2018, Hansen, Wollmuth et al. 2021, Bessa-Neto and Choquet 2023). At hippocampal CA1
42 synapses, GluA1-containing AMPAR are crucial for activity-dependent synaptic trafficking and LTP
43 (Zamanillo, Sprengel et al. 1999, Hayashi, Shi et al. 2000, Shi, Hayashi et al. 2001). However, AMPAR
44 subunit composition varies dramatically among cell types and brain regions (Schwenk, Baehrens et al.
45 2014), and our understanding of the mechanisms underlying AMPAR trafficking and function at other
46 synapses, particularly at synapses onto inhibitory neurons, is limited.

47 Structurally, AMPAR subunits contain an amino-terminal domain (ATD, a.k.a. NTD), a ligand-
48 binding domain (LBD), a transmembrane domain which forms the pore channel, and a carboxyl-
49 terminal domain (CTD). Of all these regions, the CTD is the most sequence-diverse, and has therefore
50 received considerable attention by researchers studying subunit-specific AMPAR trafficking rules
51 (Malinow and Malenka 2002, Diering and Huganir 2018, Diaz-Alonso and Nicoll 2021, Bessa-Neto and
52 Choquet 2023, Stockwell, Watson et al. 2024). The GluA2 CTD plays an important role in synaptic
53 scaling (Gainey, Hurvitz-Wolff et al. 2009, Ancona Esselmann, Diaz-Alonso et al. 2017), and the GluA4
54 CTD regulates its subcellular distribution (Boehm, Kang et al. 2006, Luchkina, Coleman et al. 2017).
55 However, it is the GluA1 CTD which has received most of the attention. GluA1 CTD interactions with
56 Protein 4.1N and Sap97 can regulate intracellular AMPAR trafficking and synaptic content (Shen, Liang
57 et al. 2000, Sans, Racca et al. 2001, Kay, Tsan et al. 2022, Bonnet, Charpentier et al. 2023). During LTP,
58 the GluA1 CTD undergoes phosphorylation by CaMKII, PKC and PKA (Barria 1997, Hayashi 2000,
59 Esteban, Shi et al. 2003), and double phospho-null mutation of Serine 831 and 845 in the GluA1 CTD has
60 been shown to block LTP (Lee, Takamiya et al. 2003). These and other studies support an essential role
61 for the GluA1 CTD in LTP. However, other evidence suggests a more nuanced role: i) the discovery that
62 CTD (Ser 831 / Ser 845)-phosphorylated GluA1 accounts for a negligible fraction of GluA1 at synapses *in*
63 *vivo* (Hosokawa, Mitsushima et al. 2015) [although another study reported a sizable proportion of

64 phosphorylated GluA1 (Diering, Heo et al. 2016)], ii) the finding that GluA1 lacking the PDZ-binding
65 motif traffics normally (Kim, Takamiya et al. 2005, Kerr and Blanpied 2012). iii), the demonstration that
66 CTD-lacking GluA1 can support basal AMPAR transmission and LTP at hippocampal CA₃→CA₁
67 synapses (Granger, Shi et al. 2013, Diaz-Alonso, Morishita et al. 2020, Watson, Pinggera et al. 2021).
68 Altogether, the emerging picture is that the presence of the GluA1 CTD is unlikely to be an absolute
69 requirement for AMPAR-mediated synaptic transmission and LTP at CA₁ PNs, where it may instead
70 play a more subtle role (Diaz-Alonso and Nicoll 2021, Bessa-Neto and Choquet 2023, Stockwell, Watson
71 et al. 2024). However, the contribution of the GluA1 CTD to synaptic transmission at other synapses,
72 especially excitatory synapses onto inhibitory neurons, remains largely unexplored.

73 The link between glutamatergic dysfunction and neuropsychiatric disorders is well-established
74 (Coyle 2006, Lisman, Coyle et al. 2008, Tamminga, Southcott et al. 2012). Specifically, the GRIA1 gene,
75 which encodes the GluA1 subunit, has been identified as a risk locus for schizophrenia in genome-wide
76 association studies (Ripke, O'Dushlaine et al. 2013, Schizophrenia Working Group of the Psychiatric
77 Genomics 2014), and postmortem analyses of individuals with schizophrenia show reduced levels of
78 GluA1 in several brain regions, including the hippocampus (Harrison 1991, Eastwood 1996, Yonezawa,
79 Tani et al. 2022). Excitatory synaptic plasticity, most importantly LTP, is disrupted in CA₁ in GluA1 KO
80 mice, which also exhibit alterations in novelty and salience processing and working memory
81 reminiscent of some of the symptoms of schizoaffective disorders (Zamanillo D.; Sprengel and Kaiser
82 1999, Reisel, Bannerman et al. 2002, Bannerman, Deacon et al. 2004, Sanderson, Sprengel et al. 2011,
83 Barkus, Feyder et al. 2012, Barkus, Sanderson et al. 2014, Bannerman, Borchardt et al. 2018, Panayi,
84 Boerner et al. 2023).

85 Using GluA1 CTD truncated (Δ CTD GluA1) mice, we found that the GluA1 CTD regulates
86 AMPAR subunit protein levels and subcellular distribution. Interestingly, the CTD is required for some
87 GluA1-dependent functions, most notably the regulation of the response to novelty as well as anxiety-
88 and despair-related behaviors, but not for GluA1-dependent memory processes. Our results suggest
89 that the GluA1 CTD modulates AMPAR synaptic transmission in a subunit composition-dependent and
90 cell type-specific manner. Altogether, this study expands our understanding of the cell-type specific
91 regulation of excitatory synaptic transmission and sheds light into the neurobiological mechanisms
92 regulating the putative schizophrenia risk-associated GluA1.

93 **Materials and Methods**

94 Animals

95 All animal procedures were approved by the Institutional Animal Care and Use Committee at
96 the University of California, Irvine (protocol numbers AUP-20-156; AUP-23-076). Mice were maintained
97 in a 12-hour light/dark schedule and had access to food and water, ad libitum. Generation of
98 homozygous HA- Δ CTD GluA1 knock-in (referred to as Δ CTD GluA1) mice was previously described
99 (Diaz-Alonso, Morishita et al. 2020). Genotyping was carried out by TransnetYX Inc.

100

101 Biochemistry

102 WT and Δ CTD GluA1 mouse forebrains were dissected and homogenized in Synaptic Protein
103 Extraction Reagent (SynPER, Thermo Scientific, #87793) with protease inhibitors (cOmplete, Roche,
104 #11836170001). Synaptosomes were then obtained following manufacturer's instructions, as in
105 (Bernard, Exposito-Alonso et al. 2022). For immunoblot, whole brain lysates and synaptosomal
106 fractions were denatured at 95 °C for 5 min. in Laemmli sample buffer (Sigma, #S-3401) and processed
107 for SDS-PAGE. Immuno-Blot PVDF membranes (Bio-Rad, #1620177) were blocked with 5% blotting
108 grade nonfat milk (Lab Scientific, #Mo841) in tris-buffered saline with 0.1% tween 20 (Sigma-Aldrich,
109 #P1379). The following primary antibodies were used at a 1:1000 dilution: guinea pig anti-GluA2 CTD
110 (Synaptic Systems, #182 105), mouse anti-GluA1 ATD (Cell Signaling, #13185S), rabbit anti-GluA3
111 (Alomone Labs, #AGC-010), rabbit anti-GluA4 (Cell Signaling, # 8070), mouse anti PSD-95 (Synaptic
112 systems, #124 011) and mouse anti-tubulin (Millipore-Sigma, #T9026). HRP-conjugated secondary
113 antibodies raised against the appropriate species were used: anti-rabbit IgG (Vector laboratories #PI-
114 1000), anti-mouse IgG (Vector laboratories #PI-2000), and anti-guinea pig IgG (Millipore Sigma
115 #AP108P). Membranes were incubated with ClarityTM Western ECL (BioRad, #170-5060). When
116 needed, membranes were incubated in stripping buffer containing Guanidine HCl and β -
117 mercaptoethanol and triton x-100 in pH 7.5 Tris HCl buffer, with gentle agitation at RT for 30 min.
118 Following incubation, membranes were rinsed, blocked and incubated with another Ab.

119

120 Confocal microscopy and image analysis

121 WT and Δ CTD GluA1 brain samples were sectioned (40 μ m, coronal) following fixation in 4%
122 paraformaldehyde. After blocking with 5% swine serum (Jackson Immuno Research, #014-000-121) and
123 2% BSA (Cell Signaling, #9998S) in permeabilizing conditions (0.1% Triton X-100, Sigma-Aldrich,
124 #T8787), samples were incubated overnight at 4° C with the following primary antibodies: rabbit anti-
125 GluA1 ATD (Cell signaling, #13185, 1:500), guinea pig anti-GluA2 (Synaptic Systems, #182 105, 1:500),

126 rabbit anti-GluA₃ (Alomone Labs, #AGC-010, 1:500), rabbit anti-GluA₄ (Cell Signaling, #8070, 1:500),
127 rabbit anti-c-Fos (Abcam, #AB190289, 1:500) and mouse anti PSD-95 (Synaptic Systems, #124 011,
128 1:500) followed by incubation with Alexa 488 goat anti-mouse (Life Technologies, #A-11001, 1:500),
129 Alexa 594 goat anti-rabbit (Life Technologies, #A11012, 1:500), Alexa 647 goat anti-rabbit (Life
130 Technologies, #A21245, 1:500) and Alexa 568 goat anti-guinea pig (Life Technologies, #A11075, 1:500)
131 secondary antibodies for 2 hours at RT. Slides were mounted with ProLong Gold Antifade Reagent with
132 DAPI (Cell Signaling Technology, #8961S).

133

134 Confocal images were collected using a Leica Sp8 confocal microscope (Leica Microsystems,
135 Wetzlar, Germany). Dorsal hippocampus field CA1 images including stratum pyramidale and stratum
136 radiatum (SR) were acquired using a 63x oil objective as a series of 20 z-steps, with a z-step size of 1 μ m,
137 at a resolution of 1024 x 1024 pixels, and a scanning frequency of 400 Hz. The optical resolution (voxel
138 size) per image was 180 nm in the xy-plane and 1.03 μ m in the z-plane. Analysis of synaptic localization
139 was performed using Imaris 9.9.1 (Bitplane, South Windsor, CT, USA) and MatLab Runtime R2022b
140 (Mathworks, Natick, MA, USA), as previously described (Bemben, Sandoval et al. 2023). Briefly, the
141 "Spots" tool was utilized to assign representative three-dimensional ellipsoid shapes to individual
142 synaptic-like GluA₁, GluA₂, GluA₃ and PSD-95 puncta. Then "Background Subtraction" was applied to
143 reduce background signal. A region of interest (ROI) was created to restrict the colocalization
144 quantification to CA1 SR. The number of spots was adjusted qualitatively using the automatically
145 generated and interactive "Quality" filter histogram to select dense signal while excluding puncta likely
146 to be background signal. To ensure an accurate spot segmentation of the underlying puncta
147 determined by size, the "Different Spots Sizes" selection was utilized, adjusting contrast with the
148 "Local Contrast" tool. The histogram was adjusted to accurate puncta coverage. Spots were then
149 rendered. Once optimal settings for each of these parameters were established for the GluA₁, GluA₂,
150 GluA₃, or PSD-95 channels, a batched protocol to automate spot detection on every image was run.
151 Threshold for colocalization was established at 0.7 μ m from the center of neighboring puncta.

152

153 Electrophysiology

154 Whole-cell patch-clamp recordings were obtained from DG GCs or GABAergic interneurons
155 (INs) using acute brain slices from 2-6 months-old male and female mice. 300 μ m horizontal slices were
156 obtained in ice-cold, oxygenated NMDG recovery solution containing (in mM): 92 NMDG, 2.5 KCl, 1.25
157 NaH₂PO₄, 30 NaHCO₃, 20 HEPES, 25 glucose, 2 thiourea, 5 Na-ascorbate, 3 Na-pyruvate, 0.5 CaCl₂•2

158 H₂O, and 10 MgSO₄•7 H₂O. pH was adjusted to 7.4 and osmolarity to 310-316 mOsm. Slices were then
159 incubated for at least 30 min. at 34 °C in artificial cerebrospinal fluid (aCSF) composed of (in mM): 119
160 NaCl, 2.5 KCl, 1 NaH₂PO₄, 26.2 NaHCO₃, 11 glucose, 2.5 and 1.3 MgSO₄. aCSF was bubbled with 95% O₂
161 and 5% CO₂. Osmolarity was adjusted to 307-310 mOsm. For recordings, slices were perfused with aCSF
162 containing 100 μM picrotoxin to block GABA A-mediated responses. Recording pipettes (3-6 MΩ) were
163 filled with internal solution containing (in mM): 135 CsMeSO₄, 8 NaCl, 10 HEPES, 0.3 EGTA, 5 QX-314, 4
164 Mg-ATP, 0.3 Na-GTP, and 0.1 spermine. Osmolarity was adjusted to 290-292 mOsm, and pH at 7.3-7.4.
165 Membrane holding current, input resistance and pipette series resistance were monitored throughout
166 experiments. Data were gathered through a IPA2 amplifier/digitizer (Sutter Instruments), filtered at 5
167 kHz, and digitized at 10 kHz. Series compensation was not performed during data acquisition. For
168 evoked EPSC recordings, a tungsten bipolar electrode was placed in the DG stratum moleculare (SM),
169 thereby stimulating perforant path (PP) inputs onto DG GCs. Electric pulses were delivered at 0.2 Hz.
170 AMPAR EPSCs were obtained while holding the cell at -70 mV; NMDAR currents were obtained at +40
171 mV. The peak evoked AMPAR response and NMDAR component 100 ms after the stimulation artifact
172 (to avoid contribution of the AMPAR EPSC) were used to calculate the AMPAR/NMDAR ratio. In paired-
173 pulse ratio (PPR) experiments, stimulation was delivered at an inter-stimulus interval of 50 ms. PPR was
174 calculated by dividing the second EPSC by the first. Input/Output (I/O) relationship was assessed by
175 stimulating PP in increments of 50 μA, from 0 μA to 500 μA. For long-term potentiation (LTP)
176 experiments, after obtaining a stable baseline, LTP was induced, no more than 6 min. after break-in,
177 using a theta-burst stimulation (TBS) induction protocol, consisting in four trains of TBS, each train
178 comprised of 5 bursts of spikes (4 pulses at 100 Hz) at 5 Hz applied to the SC fibers at 0.1 Hz, paired with
179 postsynaptic depolarization at 0 mV, as in (Traunmuller, Gomez et al. 2016). Statistical analysis was
180 performed at min. 45 after induction. Recordings from cells lost at any point between induction and the
181 end of the experiment (min. 40) were considered until that point.

182

183 Electrophysiology data was gathered and analyzed using Sutterpatch (Sutter Instruments) and
184 Igor Pro (Wavemetrics).

185

186 Behavior

187 Mice were group-housed with littermates. Mice were handled for 1 min for 4 consecutive days
188 prior to all behavioral testing. At the beginning of each testing day, mice were allowed to acclimate to
189 the behavior room for at least 30 min. before the start of the experiment. Behavioral chambers and

190 objects were cleaned and de-odorized between mice. Behavioral scoring was done by a researcher blind
191 to the genotype. Initial behavioral assessments performed at the Gladstone Institute Behavior Core
192 used male mice only. Subsequent studies at UC Irvine included both male and female mice, and data
193 from both sexes were pooled.

194

195 *Open Field (OF)*: Mice were placed at the center of an OF arena and allowed to explore for 15 min. In the
196 Gladstone experiments, activity was recorded in a clear acrylic (41 x 41 x 30 cm) chamber using a Flex-
197 Field/Open Field Photobeam Activity System (San Diego Instruments, San Diego, CA) with two 16 x 16
198 photobeam arrays that automatically detected horizontal and vertical (rearing) movements. Rearings
199 were also quantified. In the UCI experiments, locomotor activity was recorded by an overhead camera
200 in a white, 30 x 23 x 23 cm plastic chamber and total distance traveled was analyzed using a tracking
201 analysis code written in MatLab (Github: <https://github.com/HanLab-OSU/MouseActivity>). The center /
202 total movement ratio was calculated.

203

204 *Object Location Memory (OLM) task*: Mice were habituated to a white Plexiglas chamber (30 x 23 x 23 x
205 cm) for 5 min. daily for 4 days. On the training day, mice were placed in the chamber with two identical
206 objects and allowed to explore them for 10 min. On the test day, 24 hours later, mice were placed in the
207 chamber with either object displaced to a different location and allowed to explore the arena for 5 min.
208 Object identity was counterbalanced between genotypes. The animal's behavior was recorded using an
209 overhead camera and object exploration time scored using the criteria described by (Vogel-Ciernia and
210 Wood 2014). Discrimination index (DI) was calculated as follows: $(\text{Novel Object Time} - \text{Familiar Object Time}) / (\text{Novel Object Time} + \text{Familiar Object Time}) \times 100$. A DI score of +20 or greater was determined
211 as learning. DI was calculated for both training and test day. Exclusion criteria: Mice that scored ± 20
212 preference for an individual object on training day and mice that explored the objects less than 3
213 seconds were excluded from analysis.

214

215
216 *Novel Objection Recognition (NOR) task*: Mice handling and habituation were as described for the OLM
217 task. On training day, mice were placed in the chamber with two identical objects and allowed to
218 explore them for 10 min. The following day (test day), mice were placed back in the chamber with one
219 familiar and one novel object and allowed to explore for 5 min. The identity of the novel object was
220 counterbalanced between genotypes. Discrimination index was calculated as described for OLM.

221

222 *Forced Alternation Y-maze*: The forced alternation task was performed using an opaque Plexiglas Y-
223 maze. Each arm was 36 x 21 x 10 cm. On the training trial, mice were placed into a starting arm, facing
224 the center of the maze, and allowed to explore two of the arms for 5 min., while the third arm was
225 blocked. After an inter-trial interval of 1 min., mice were placed back in the maze at the same starting
226 arm and allowed to explore all three arms for 5 min. The starting arm and blocked arm were
227 counterbalanced across mice. The maze was cleaned and deodorized with 70% ethanol between trials.
228 Total number of arm crossings and time spent in each arm was scored using a mouse tracking software
229 (Any-Maze, Stoelting Co). Mice were required to enter an arm with at least 2/3 of its body to be
230 considered a crossing. DI was calculated as Novel Arm Time / (Novel Arm Time + Non-Starting Arm) x
231 100 (Wolf et al., 2016).

232
233 *Elevated Plus Maze*: Mice were placed in the center of an elevated maze with two open arms (without
234 walls, 38 x 5 cm) and two closed arms (with 16.5 cm tall walls), the intersection of the arms was 5 x 5 cm,
235 and the entire maze is elevated 77.5 cm above the ground (Hamilton-Kinder, Poway, CA). Total time
236 spent and distance traveled in each arm were measured across the 10-min session.

237
238 *Forced Swim Test*: Mice were individually placed in a clear plastic cylinder (25.5 cm diameter x 23 cm
239 height), filled with water at 24 °C, for 5 min. The total time spent immobile in the last 3 min. of the task
240 was scored. Floating, balancing and idle swimming were considered immobility (Can, Dao et al. 2012).

241
242 *Light/Dark Transition Test*: The light-dark apparatus consisted of an opaque acrylic box (42 x 21 x 25 cm)
243 divided into two compartments (2/3 light, 1/3 dark) with a small opening connecting the two chambers.
244 The light compartment was made of opaque white walls and lit by an overhead lamp, while the dark
245 compartment was unlit and made of black non-transparent acrylic walls. Mice were first placed in the
246 light compartment and allowed to freely explore both chambers for 10 min. The time spent in each
247 chamber, number of crossings, and the latency to enter the dark chamber was recorded using Any-
248 Maze (Stoelting Co.).

249
250 *Contextual Fear Paradigm*: Fear conditioning experiments were conducted using a Med Associates
251 VideoFreeze system. The fear conditioning chamber (24 x 30.5 x 21.5 cm) sits inside a sound
252 attenuating shell (63.5 x 75 x 35.5 cm, Med Associates, Fairfax, Vermont). On the training day, mice
253 were placed into a conditioning chamber and four-foot shocks (0.45 mA, 2s) were delivered at min. 5, 7,

254 9, and 11 of a 13-minute training period. The following day (context recall test), mice were exposed to
255 the conditioned context in the absence of foot shocks for 10 min. Fear generalization was assessed 48
256 hours after the initial training in a different context in a 10 min. session. In this generalization context,
257 tactile, visual, auditory, and olfactory stimuli were all distinct from the training context. Freezing
258 behavior was measured at baseline and during conditioning, the contextual recall test, and the
259 generalization test.

260

261 For the pre-exposure experiment, on the pre-exposure day mice were placed into the
262 conditioning chamber for 30 min., with no foot shocks. 24 hours later, on conditioning day, mice were
263 placed back into a conditioning chamber for 13 min, with four foot shocks (0.6mA, 2s) delivered at min.
264 5, 7, 9, and 11. 24 hours later, on the third day, mice were placed into the conditioned context in the
265 absence of foot shocks for a context recall test, where freezing was measured across a 10 min period.
266 The chamber context remained the same over all three days.

267

268 Shock reactivity was measured during training by the VideoFreeze system and expressed as the
269 max motion index.

270

271 *Hot plate test*: Hot plate nociception was measured on a black anodized, aluminum plate (IITC Life
272 Science, Woodland Hills, CA) heated to 52°C. Latency to withdraw one of the hind paws from the plate
273 was measured to the nearest hundredth of a second.

274

275 Stereotaxic Viral Injection

276 Mice were anesthetized using isoflurane and bilaterally injected using a pulled glass pipette in the
277 hippocampal DG field (AP: -3.39, ML: ± 2.50 , DV: -3.4, -2.9, -2.4) with 1 μ l pAAV-mDlx-GFP-Fishell-1
278 (83900-AAV1), kindly shared by Dr. Gordon Fishell (Dimidschstein, Chen et al. 2016) and purchased
279 from Addgene.

280

281 Statistical Analysis

282 Data analysis throughout the study was done blind to the experimental condition when possible.
283 Results shown represent the mean \pm SEM. The number of independent experiments or biological
284 samples, and the statistical test employed, are indicated in every case. Statistical analyses were
285 performed using GraphPad Prism 9 and SutterPatch software.

286

287 **Results**

288 Truncation of the GluA1 CTD affects AMPAR levels and subcellular distribution.

289 Here we set out to investigate the influence of the GluA1 CTD in AMPAR trafficking, synapse
290 type-specific synaptic transmission and plasticity, cognitive function, novelty processing and other
291 behaviors using Δ CTD GluA1 mice (Fig. 1A). First, we examined whether GluA1 CTD truncation affects
292 AMPAR subunit levels. We observed that GluA1 levels were significantly reduced in Δ CTD GluA1
293 forebrain lysates compared to their WT counterparts', yet no differences were observed in
294 synaptosome-enriched fractions (Fig. 1B, C). These findings suggest that the loss of the CTD reduces
295 GluA1 expression or stability, but does not alter GluA1's synaptic content. In contrast, GluA2 levels were
296 strongly upregulated in Δ CTD GluA1 samples, both globally and in the synaptic fraction (Fig. 1B, D).
297 GluA3 levels were unaffected (Fig. 1B, E). Finally, we observed a modest, statistically significant
298 increase in GluA4 levels in Δ CTD GluA1, yet only in synaptic fractions (Fig. 1B, F).

299

300 We then examined whether GluA1 CTD truncation affects subcellular AMPAR localization.
301 Using an antibody against the GluA1 ATD, which detects both WT and Δ CTD truncated GluA1, we
302 observed that, as expected, GluA1 immunoreactivity (i.r.) was largely absent from the somata-enriched
303 strata pyramidale (SP) in hippocampal fields CA1-CA3 and granulare (SG) in DG in WT samples.
304 Meanwhile, the subcellular distribution of Δ CTD GluA1 was more diffuse, suggesting impaired
305 intracellular trafficking (Fig. 1G). Quantification of the soma/dendrite GluA1 ir ratio in CA1 and DG
306 revealed a significant accumulation of Δ CTD GluA1 in the soma in both regions (Fig. 1H, I), suggesting
307 that GluA1 CTD truncation impairs AMPAR soma→dendrite trafficking in CA1 PNs and DG GCs.
308 Interestingly, GluA2 subunits showed a similar redistribution in CA1 (Fig. 1J, K), reminiscent of the
309 pattern found in GluA1 KOs (Zamanillo D.; Sprengel and Kaiser 1999). GluA2 distribution was not
310 significantly altered in DG (Fig. 1J, L). We then turned to confocal microscopy to further analyze GluA1
311 and GluA2 distribution in field CA1 SR and in DG SM, where most excitatory synapses onto CA1 PNs
312 and DG GCs, respectively, occur. Consistent with our previous observations, we found a significant
313 decrease in the density of putative synaptic GluA1 puncta in both CA1 SR and DG SM (Suppl. Fig. 1A, C).
314 The density of the excitatory postsynaptic marker PSD-95 puncta was slightly reduced in CA1 SR (Suppl.
315 Fig. 1B), but not significantly altered in DG SM (Suppl. Fig. 1D). Despite the significant redistribution of
316 GluA1, its colocalization with PSD-95 was unaffected in both regions in Δ CTD GluA1 samples (Fig. 1M,
317 N), suggesting that Δ CTD GluA1 localization at synapses was not significantly affected. In hippocampal

318 PNs, GluA1/A2 heterotetramers are the most prevalent AMPAR composition, followed by GluA2/A3 (Lu,
319 Shi et al. 2009). To reveal possible compensatory changes in AMPAR subunit composition in Δ CTD
320 GluA1 mice, we assessed the distribution of GluA2 and GluA3. Putative synaptic puncta densities were
321 not altered in CA1 SR or DG SM (Suppl. Fig. 1E-H), and neither was their colocalization (Fig. 1O, P).
322 Altogether, these findings indicate that loss of the GluA1 CTD affects intracellular trafficking, but that
323 the synaptic AMPAR complement is largely intact (Fig. 1Q).

324

325 Δ CTD GluA1 mice exhibit novelty-induced hyperlocomotion but intact cognitive function.

326 Having established the impact of GluA1 CTD truncation in AMPAR levels and subcellular
327 distribution, we sought to clarify whether GluA1-dependent regulation of cognitive function and
328 behavior require the CTD. Previous studies have shown that GluA1 KO mice have impaired spatial
329 working memory, but intact or even enhanced long-term memory (Sanderson, Good et al. 2009).
330 Novelty-induced hyperlocomotion is one of the most robust and reproducible phenotypes in GluA1 KO
331 mice (Zamanillo D.; Sprengel and Kaiser 1999, Bannerman, Deacon et al. 2004, Procaccini, Aitta-aho et
332 al. 2011). To assess the contribution of the GluA1 CTD to spatial novelty processing, we quantified
333 locomotion in the open field (OF) test in WT and Δ CTD GluA1 mice. Initially we tested male WT and
334 homozygous Δ CTD GluA1 mice, and observed a strong exacerbation of novelty-induced locomotion in
335 Δ CTD GluA1 mice compared to WTs (Fig. 2A). The center/total distance ratio was similar in WT and
336 Δ CTD GluA1 mice (Suppl. Fig. 2A). Δ CTD GluA1 mice made significantly fewer fine movements (Suppl.
337 Fig. 2B) and a similar number of rearings (Suppl. Fig. 2C) compared to their WT counterparts. In a
338 different cohort, Δ CTD GluA1 male and female mice showed indistinguishable exacerbated novelty-
339 induced hyperlocomotion, which was absent in heterozygous mice (Suppl. Fig. 2D).

340

341 Next, we assessed the role of the GluA1 CTD in cognitive function. We previously demonstrated
342 that GluA1 CTD truncation does not affect spatial reference memory (Diaz-Alonso, Morishita et al.
343 2020). In the forced alternation Y-maze (Fig. 2B), which is used to assess spatial working memory in
344 mice, WT and Δ CTD GluA1 male and female mice performed comparably (Fig. 2C). Then, we tested
345 long-term spatial memory in the object location memory task (OLM, Fig. 2F). As expected from the OF
346 results, we observed enhanced locomotion in Δ CTD GluA1 male and female mice in their first exposure
347 to the OLM arena. To avoid its potential confounding effect, we habituated mice to the OLM arena.
348 After 4 days, hyperlocomotion was no longer observed, indicating that Δ CTD GluA1 mice were
349 habituated (Fig. 2D, E). Still, total locomotion during OLM training and test were significantly different

350 between genotypes (Suppl. Fig. 2E, F), possibly driven by the introduction of novel objects in the arena.
351 Consistent with this possibility, object exploration was also significantly greater in Δ CTD GluA1 mice
352 during training and test (Suppl. Fig. 2G, H). Interestingly, Δ CTD GluA1 male and female mice showed
353 superior discrimination of the displaced object compared to WT mice (Fig. 2G). We explored whether
354 increased object exploration in Δ CTD GluA1 mice underlies their superior performance, but we found
355 no correlation between distance travelled or object exploration time and performance in the OLM test
356 (Suppl. Fig. 2M, N). In the novel objection recognition task (NOR, Fig. 2H), novel object discrimination
357 was comparable between male and female Δ CTD GluA1 and WT counterparts (Fig. 2I). Neither total
358 locomotion nor total object exploration during NOR training and test were significantly different
359 between genotypes (Suppl. Fig. 2J-L).

360

361 Impaired fear expression in Δ CTD GluA1 mice.

362 Contextual fear conditioning and memory are impaired in GluA1 KO mice (Humeau, Reisel et al.
363 2007). Similarly, Δ CTD GluA1 mice did not exhibit freezing behavior during the conditioning phase (Fig.
364 2K, L). Decreased freezing was unlikely due to impaired sensory processing in Δ CTD GluA1 mice, which
365 showed enhanced responsiveness in the hot plate test (Suppl. Fig. 2O) and higher motion indices in
366 response to the two initial foot shocks (0.45 mA) delivered during conditioning (Suppl. Fig. 2P).
367 Unexpectedly, Δ CTD GluA1 mice showed freezing comparable to WTs in the 24 h recall test (Fig. 2M, N),
368 in stark contrast to GluA1 KOs, which show impaired fear expression and memory (Humeau, Reisel et al.
369 2007). In both WT and Δ CTD GluA1 animals, the % freezing during conditioning was not predictive of
370 freezing during the 24 h recall test (Suppl. Fig. 2Q). These findings support that GluA1-dependent
371 contextual memory formation does not require the CTD. Fear generalization was not affected either,
372 supporting that context discrimination and memory function is intact in Δ CTD GluA1 mice (Suppl. Fig.
373 2R, S).

374

375 Next, we sought to identify the mechanism underlying the apparent discrepancy between
376 impaired contextual fear expression (Fig. 2K, L) and intact contextual memory (Fig. 2M, N). We
377 hypothesized that the exacerbated context novelty-driven hyperlocomotion in Δ CTD GluA1 mice
378 masks freezing during conditioning, although it does not affect contextual memory formation. If this
379 prediction were true, we would expect that reducing context novelty (hence decreasing
380 hyperlocomotion) would unmask freezing during fear conditioning. We tested this by assessing
381 contextual fear expression after a 30-min. context pre-exposure session 24 h prior to conditioning (Fig.

382 3A). Context pre-exposure did not affect freezing during conditioning or contextual memory in WT mice
383 (Fig. 3B, E) but, as predicted, partially normalized freezing in Δ CTD GluA1 mice (Fig. 3B, C). As expected
384 from previous findings (Fig. 2M, N), performance at the 24-hour recall test was indistinguishable from
385 that of WT mice (Fig. 3D, E). Shock response was indistinguishable between Δ CTD GluA1 and WT mice
386 in this cohort (Suppl. Fig. 3). These findings support the notion that the GluA1 CTD plays a critical
387 regulatory role in novelty processing, but is not required for GluA1-dependent memory.

388

389 Additional schizoaffective disorder-related behavioral alterations evoked by GluA1 CTD truncation.

390 Next, we studied whether GluA1 CTD truncation alone is sufficient to elicit other behavioral
391 alterations relevant to schizoaffective disorders. In the elevated plus maze (EPM, Fig. 4A), Δ CTD GluA1
392 male mice spent a greater proportion of the time exploring the open arms (Fig. 4B) throughout the
393 session (Suppl. Fig. 4A). Consistently, the number of open arm entries (Fig. 4C) and distance (Suppl. Fig.
394 4B), but not closed arm entries (Fig. 4D) and distance (Suppl. Fig. 4C) were increased in male Δ CTD
395 GluA1 mice. Consistent with previous results (Fig. 2A, Suppl. Fig. 2D), Δ CTD GluA1 mice displayed an
396 overall increase in total distance traveled in the EPM relative to their WT counterparts (Suppl. Fig. 4D).
397 The observed heightened exploration of open arms in the EPM in Δ CTD GluA1 mice is reminiscent of
398 the GluA1 KO mice phenotype (Fitzgerald, Barkus et al. 2010), albeit perhaps exacerbated. To further
399 explore the apparently reduced anxiety in Δ CTD GluA1 mice, we applied the light/dark transition test,
400 which can also reveal changes in anxiety-like behavior (Fig. 4E). Latency to enter the dark (safe) zone
401 was increased in Δ CTD GluA1 male and female mice (Fig. 4F). The total time spent in each zone was not
402 altered (Suppl. Fig. 4E). Additionally, in the forced swim test (FST, Fig. 4G), used to measure despair-
403 like behavior in rodents, we found that Δ CTD GluA1 male and female mice spent less time immobile
404 compared to their WT counterparts (Fig. 4H). Latency to immobility was not significantly affected
405 (Suppl. Fig. 4F). These findings indicate that the CTD is required for GluA1-dependent novelty
406 processing and regulates risk assessment, approach behavior and/or anxiety. Conversely, our data
407 indicates that the CTD is not required for GluA1-dependent memory processes.

408

409 Exacerbated neuronal activity in the DG in Δ CTD GluA1 mice following exposure to a novel 410 environment.

411 To identify the neurobiological mechanism underlying the regulation of novelty processing by
412 the GluA1 CTD, we sought to identify neuronal populations which respond to novelty in a GluA1 CTD-
413 dependent fashion. To this end, we quantified c-Fos expression, a proxy for neuronal activation, two

414 hours after exposure to a novel environment (Fig. 5A). Increased c-Fos-labelled cells were observed in
415 various brain regions in WT male and female mice upon exposure to a novel context (Fig. 5, Suppl. Fig.
416 5). In dorsal hippocampus, c-Fos induction was exacerbated in putative DG GCs and field CA₃ PN in
417 Δ CTD GluA1 male and female mice compared to WT after OF exposure (Fig. 5B-D). c-Fos expression
418 increased to a similar degree in WT and Δ CTD GluA1 mice in field CA₁ (Fig. 5E). The similarity of these
419 results with those previously reported in GluA1 KO mice (Procaccini, Aitta-aho et al. 2011), suggests
420 that the CTD is critically required for GluA1-dependent regulation of hippocampal activity upon
421 exposure to a novel context.

422

423 The GluA1 CTD regulates excitatory synapses onto dentate gyrus GABAergic interneurons.

424 Excessive c-Fos expression in GCs in Δ CTD GluA1 mice can ensue as a consequence of altered
425 synaptic transmission onto these cells. To test this possibility, we obtained whole-cell patch-clamp
426 recordings from DG GCs using acute brain slices from Δ CTD GluA1 and WT mice (Fig. 6A) and examined
427 excitatory synaptic transmission at perforant path (PP)→GC synapses. We observed no significant
428 changes in AMPAR/NMDAR ratios (Fig. 6B), indicating that AMPAR-mediated transmission is not
429 severely affected in Δ CTD GluA1 DG GCs. Consistently, input/output AMPAR EPSC analysis showed no
430 significant differences either (Fig. 6C), confirming that AMPAR-mediated synaptic transmission is
431 largely intact in these cells. Then, we assessed whether the loss of the GluA1 CTD affects LTP at
432 PP→DG GC synapses. We found a small, non-statistically significant reduction in GCs LTP in Δ CTD
433 GluA1 mice (Fig. 6D). Altogether, these results suggest that alterations in synaptic transmission and
434 LTP in DG GCs are unlikely to underlie the exacerbated neuronal activation observed following novel
435 context exposure.

436

437 Local INs provide inhibitory inputs to DG GCs, thus regulating their excitability, spike timing,
438 and lateral inhibition, and ultimately contributing to the sparse activity of DG GCs (Akgul and McBain
439 2016, Pelkey, Chittajallu et al. 2017, Espinoza, Guzman et al. 2018). We hypothesized that GluA1 CTD
440 truncation might affect AMPAR-mediated excitatory synaptic transmission onto GABAergic INs in DG,
441 thereby compromising circuit inhibition and potentially leading to the observed GCs 'priming'. To
442 identify inhibitory cells, we bilaterally injected an AAV-mDLX-GFP, which labels forebrain GABAergic
443 INs, into the DG of WT and Δ CTD GluA1 littermates. After ~4 weeks of expression, GABAergic cells
444 were labelled throughout the hippocampus in acute slices (Fig. 6E). We obtained whole-cell recordings
445 from putative DG parvalbumin (PV)+ basket cells, identified by their morphology and localization of the

446 soma within SG. We found a significant reduction in AMPAR/NMDAR ratios in these cells (Fig. 6F),
447 indicating that the loss of the GluA1 CTD affects synaptic transmission in DG GABAergic INs, in contrast
448 to the intact synaptic transmission observed onto GCs. The specific reduction of excitatory synaptic
449 drive onto DG GABAergic cells explains, at least in part, the exacerbated DG responsiveness to novelty
450 and subsequent behavioral alterations observed in Δ CTD GluA1 mice.

451

452 Discussion

453 GluA1-deficient mice exhibit deficits in synaptic plasticity and behavioral alterations, such as
454 selective deficits in short-term habituation and exacerbated novelty-induced locomotor hyperactivity,
455 reminiscent of some of the features of schizoaffective disorders and neurodevelopmental conditions
456 including attention-deficit/hyperactivity disorder (Fitzgerald, Barkus et al. 2010, Barkus, Feyder et al.
457 2012, Barkus, Sanderson et al. 2014). Consistently, mutations in the *GRIA1* gene, which encodes GLUA1,
458 may increase risk of schizophrenia in humans (Coyle 2006, Ripke, O'Dushlaine et al. 2013,
459 Schizophrenia Working Group of the Psychiatric Genomics 2014, Ismail, Zachariassen et al. 2022,
460 Yonezawa, Tani et al. 2022).

461

462 What makes GluA1 unique among AMPAR subunits? The GluA1 CTD is the most sequence-
463 diverse area of the receptor and has therefore drawn considerable attention for decades. Despite the
464 interest, its role, especially at synapses outside of hippocampal field CA1, is largely unexplored. In this
465 study, we used constitutive GluA1 CTD-truncated mice to explore crucial aspects of how the CTD
466 affects GluA1's localization and function at the biochemical, cellular and behavioral level. We found that
467 the GluA1 CTD regulates AMPAR subunit protein levels, intracellular trafficking and synaptic
468 transmission onto inhibitory, but not excitatory neurons in the DG, ultimately affecting GC excitability
469 and spatial novelty processing. We found no evidence of memory impairments upon loss of the GluA1
470 CTD, and in fact we observed enhanced performance in OLM. Altered performance in the FST, EPM
471 and light/dark alternation tests suggest additional regulation of affective processes by the GluA1 CTD.

472

473 In a previous study we did not observe qualitative changes in AMPAR subunit expression in
474 Δ CTD GluA1 mice (Diaz-Alonso, Morishita et al. 2020). However, more detailed analysis in this study
475 revealed that GluA1 subunit levels and subcellular distribution are, in fact, affected by the loss of the
476 GluA1 CTD. We also found that the CTD influences intracellular GluA1 trafficking, consistent with
477 previous reports highlighting the importance of GluA1 CTD interactions with 4.1N and SAP97 in

478 intracellular AMPAR trafficking (Shen, Liang et al. 2000, Sans, Racca et al. 2001, Bonnet, Charpentier et
479 al. 2023). Interestingly, despite reduced GluA1 levels and altered intracellular trafficking, we found that
480 both GluA1's abundance at synaptosomes and its colocalization with PSD-95 were not significantly
481 affected by truncation of the CTD. These findings suggest that, despite reduced soma→dendrite
482 trafficking, synaptic AMPAR docking is not significantly affected by the truncation of the GluA1 CTD.
483 This is consistent with the normal AMPAergic transmission in Δ CTD GluA1-expressing CA1 PNs
484 (Granger, Shi et al. 2013, Diaz-Alonso, Morishita et al. 2020, Watson, Pinggera et al. 2021) and DG GCs
485 (present study).

486 GluA2 protein levels were dramatically increased in Δ CTD GluA1 mice, in stark contrast with the
487 unaltered or even reduced GluA2 levels reported in GluA1 KO mice (Zamanillo, Sprengel et al. 1999,
488 Jensen, Kaiser et al. 2003). Furthermore, GluA2, but not GluA3 subunits, also appeared enriched in the
489 soma in Δ CTD GluA1 mice, suggesting that GluA2 can form stable heteromeric receptors with Δ CTD
490 GluA1 and that the GluA1 CTD exerts a significant influence in intracellular trafficking of GluA1/A2
491 AMPARs. Altogether, these findings support the notion that the GluA1 subunit, both via its ATD (Diaz-
492 Alonso, Sun et al. 2017) and its CTD (present study), dominate heteromeric AMPAR trafficking.
493 Together with the normal levels and localization observed for GluA3, and the unaltered GluA2/A3
494 colocalization in Δ CTD GluA1 hippocampi, these findings suggest that CTD-lacking GluA1 partakes in
495 synaptic transmission similarly to WT GluA1, and that the normal synaptic transmission and plasticity
496 observed at CA1 PNs and DG GCs are not a result of a replacement of GluA1-containing AMPARs by
497 GluA2/A3 heteromers.

498 The mechanisms regulating AMPAR trafficking and synaptic complement are poorly
499 understood outside of hippocampal field CA1, despite the prevalence of AMPAR-mediated synaptic
500 transmission throughout the CNS. Here we found that DG GCs are "primed" in Δ CTD GluA1 mice, and
501 become excessively active following spatial novelty exposure, presumably contributing to
502 hyperlocomotion. A recent study offered a plausible explanation for GC overactivity in Δ CTD GluA1
503 mice, showing that AMPAR EPSCs are enhanced in GCs overexpressing CTD-lacking GluA1, which
504 escapes SAP97-mediated retention at perisynaptic sites (Kay, Tsan et al. 2022). In this study, we did not
505 find increased AMPAR EPSCs in Δ CTD GluA1 mice, possibly because of the different approach
506 (constitutive GluA1 CTD truncation vs acute overexpression of CTD-truncated GluA1) or species (mouse
507 vs rat) employed in the two studies. Instead, we found an alternative possibility: AMPAR EPSCs on DG
508 inhibitory INs are significantly smaller in Δ CTD GluA1 mice, which conceivably leads to decreased

509 inhibition onto DG GCs and may thereby render DG GCs prone to overactivation by excitatory inputs,
510 especially those conveying novelty. These findings are consistent with a previous report showing that
511 chemogenetic hippocampal inhibition normalized novelty-induced locomotion in GluA1 KO mice
512 (Aitta-Aho, Maksimovic et al. 2019). Our results suggest that, while altered AMPAR subunit levels and
513 intracellular trafficking affect various neuron types in Δ CTD GluA1 mice, certain AMPAR subunit
514 compositions, such as the GluA1/GluA4 heteromers that dominate in fast-spiking PV+ INs, are
515 particularly sensitive to the truncation of the GluA1 CTD. Meanwhile, excitatory neurons may more
516 easily compensate the truncation of the GluA1 CTD. The increased levels of GluA4, whose expression is
517 essentially restricted in the forebrain to PV+ INs, is additional support for their specific vulnerability in
518 the Δ CTD GluA1 DG. Alternatively, it may hint a compensatory mechanism involving this cell
519 population.

520

521 PV+ INs dysfunction can contribute to the pathophysiology of schizophrenia (Lisman, Coyle et
522 al. 2008, Curley and Lewis 2012, Marin 2012, Ruden, Dugan et al. 2021). Altered AMPAR function in PV+
523 INs can significantly affect their output and function, as exemplified in PV+ IN-specific GluA1 KO mice,
524 which show impaired short-term habituation (Fuchs, Zivkovic et al. 2007), and excitation/inhibition
525 imbalance reminiscent of that found in patients with schizophrenia (Chen-Engerer, Jaeger et al. 2022).
526 Other manipulations such as the deletion of ErbB4 in PV+ INs, which lead to a reduction in AMPAR
527 content in excitatory synapses onto PV+INs, also result in schizophrenia-related phenotypes (Del Pino,
528 Garcia-Frigola et al. 2013). The important role of the GluA1 CTD supporting excitatory synapses onto
529 putative PV+ INs unveiled in this study expands our understanding of the mechanisms underlying cell
530 type-specific AMPAR transmission, disruptions of which potentially contribute to altered synaptic
531 transmission in schizoaffective disorders.

532

533 Our study discriminates between CTD-dependent and independent GluA1 cognitive processes:
534 on one hand, we demonstrate that spatial working memory, object recognition memory and long-term
535 contextual fear memory – all of which are impaired in GluA1 KO mice (Reisel, Bannerman et al. 2002,
536 Humeau, Reisel et al. 2007, Sanderson, Good et al. 2009), are not affected by the loss of the GluA1 CTD.
537 Remarkably, OLM is enabled after subthreshold training. On the other hand, we find that GluA1 CTD
538 truncation alone is sufficient to reproduce aberrant salience, short-term habituation and general
539 response to novelty. The normalization of fear expression during contextual fear conditioning by
540 context pre-exposure suggests that disrupted fear response in Δ CTD GluA1 mice is secondary to altered

541 novelty processing. Altogether, our findings clearly demonstrate that GluA1-dependent regulation of
542 novelty processing necessitates the CTD.

543

544 GluA1 KO mice are considered a valuable tool to study altered synaptic function in
545 schizophrenia (Fitzgerald, Barkus et al. 2010, Barkus, Feyder et al. 2012, Bygrave, Jahans-Price et al.
546 2019). Here we found that GluA1 CTD truncation alone recapitulated the schizoaffective-relevant
547 behaviors present in GluA1 KO mice. Specifically, the increase in approach behavior in the elevated plus
548 maze, light/dark transition and forced swim tests can be interpreted as reduced anxiety / depression,
549 but may also reflect increased novelty-seeking or risk-taking, recapitulating and even exacerbating
550 some of the symptoms of schizophrenia and ADHD previously observed in constitutive GluA1 KOs.
551 Similar to genetic deletion of GluA1, the behavioral consequences of GluA1 CTD truncation are complex,
552 and a complete, accurate interpretation will require additional studies.

553

554 In summary, this study provides a comprehensive characterization of the GluA1 CTD roles in
555 AMPAR subunit levels, intracellular trafficking, cell type-specific synaptic transmission and GluA1-
556 dependent affective and memory processes. Our study identifies the GluA1 CTD as a crucial element in
557 the AMPAR complex that regulates the strength of excitatory synapses onto inhibitory INs, and
558 suggests that Δ CTD GluA1 mice may be valuable to study features of schizoaffective and other
559 psychiatric disorders.

560

561 **Acknowledgments**

562 We would like to thank Dr. Roger Nicoll for supporting initial experiments in his laboratory. Dr.
563 Mulatwa T. Haile and Dr. Lulu Y. Chen for guidance and equipment used in behavior assessments, and
564 the Diaz-Alonso lab members for fruitful discussions. This work is supported by grants K99/Roo
565 MH118425, Whitehall Foundation, Brain and Behavior Research Foundation and UCI start-up funds to
566 J.D.-A. and AG076835 to M.A.W. G.S. is supported a the T32 Training Program in Epilepsy Research
567 (T32NS045540). C.A.C. is supported by an HHMI Gilliam's Fellowship. A.M. is supported by the NIH-
568 NIGMS Maximizing Access to Research Careers T34 (#GM136489). M.A.S. is supported by a Eugene
569 Cota-Robles fellowship and the Howard Schneiderman T32 Training Program in Learning and Memory
570 (#T32MH119049). V.A.V. is supported by the NRSA DA059982 fellowship. The Optical Biology Core
571 Facility of the Developmental Biology Center is supported by grants CA-62203 and GM-076516.

572

573 **Author contributions**

574 G.S. performed and analyzed electrophysiology experiments; A.V.K. performed and analyzed
575 biochemistry experiments; G.S., A.V.K and M.A.S. performed and analyzed histology experiments; G.S.,
576 A.V.K., C.A.C., A.M., V.A.V., I.L., J.S. and M.A.W. performed and analyzed behavior experiments; G.S
577 and J.D.-A. drafted, and all authors edited the manuscript. J.D.-A. coordinated the study.

578

579 **Conflict of Interest**

580 The authors declare no competing interests.

581

582 **Figure legends**

583 **Figure 1. AMPAR subunit levels and subcellular distribution are affected by the loss of the GluA1**
584 **CTD.**

585 A: Schematic depicting CTD truncation in Δ CTD GluA1 mice. B: Schematic of synaptosomal
586 fractionation (left) and immunoblot from whole-brain lysate (WBL) and synaptosomal fractions of WT
587 and Δ CTD GluA1 (right). C-F: GluA1 (C), GluA2 (D), GluA3 (E), and GluA4 (F) levels normalized to α -
588 tubulin from WT WBL. G: GluA1 ATD staining (red) in WT and Δ CTD GluA1 hippocampus. H-I: Average
589 soma / dendrite ratio of GluA1 signal in CA1 and DG, respectively. J: GluA2 staining (green) in WT and
590 Δ CTD GluA1 hippocampus. K-L: Average soma/dendritic ratio of GluA2 in WT and Δ CTD GluA1 mice for
591 hippocampal field CA1 and DG, respectively. M, N: Representative immunostaining of GluA1 (red) and
592 PSD-95 (cyan) in CA1 and DG in WT and Δ CTD GluA1 samples (top) and colocalization quantification
593 (bottom). O, P: Representative immunostaining of GluA2 (red) and GluA3 (cyan), in CA1 and DG in WT
594 and Δ CTD GluA1 samples (top) and colocalization quantification (bottom). Q: Schematic of subcellular
595 distribution of GluA1 and GluA2 in CA1 and DG in WT and Δ CTD GluA1 PNs. S.P., Stratum pyramidale;
596 S.R., Stratum radiatum; S.M., Stratum moleculare; S.G., Stratum granulare. Scale bar: G, J, 200 μ m; M-
597 P, 10 μ m. Error bars represent SEM. n.s., not statistically different; *, $p \leq 0.05$; **, $p \leq 0.01$; ***, $p \leq 0.001$;
598 ****, $p < 0.0001$. C-F: one-way ANOVA. H-P: unpaired t-test.

599

600 **Figure 2. Δ CTD GluA1 mice exhibit novelty-induced hyperlocomotion and impaired fear expression,**
601 **but intact memory.**

602 A: Mean distance traveled during habituation phase for WT and Δ CTD GluA1 mice. B: Schematic of
603 forced alternation Y-maze task. C: Time in novel arm relative to total time in novel and familiar arms for
604 WT and Δ CTD GluA1 mice. D: Representative track plots overlaid atop heat maps of WT (left) and

605 Δ CTD GluA1 (right) mice during habituation day 1 and 4. E: Mean distance traveled across time during
606 habituation for WT and Δ CTD GluA1 mice. F: Schematic of object location memory (OLM) task (left)
607 and representative heat maps (right) of WT and Δ CTD GluA1 mice during training and test day. G:
608 Discrimination index during training and test sessions for WT and Δ CTD GluA1 mice in the OLM task. H:
609 Schematic of novel object recognition (NOR) task (left) and representative heat maps (right) of WT and
610 Δ CTD GluA1 mice during training and test day. I: Discrimination index during training and test sessions
611 for WT and Δ CTD GluA1 mice in the NOR test. J: Schematic of contextual fear conditioning test. K, L:
612 Freezing during training (K) and during the 24-hour contextual recall (L) during contextual fear
613 conditioning for WT and Δ CTD GluA1 mice. Foot shocks are indicated with vertical red dashed lines. M,
614 N: Freezing % across time (M) and average freezing % (N) during context recall test for WT and Δ CTD
615 GluA1 mice. Error bars represent SEM. Empty dots represent females, filled dots represent males. n.s.,
616 not statistically different; *, $p \leq 0.05$; ***, $p \leq 0.001$; ****, $p \leq 0.0001$. A, E, K, M: two-way ANOVA. C:
617 unpaired t-test. G, I: paired t-test. L: Mann-Whitney test. N: Welch's t test.

618

619 **Figure 3. Pre-exposure to the context prior to fear conditioning partially rescues freezing behavior**
620 **in Δ CTD GluA1 mice.**

621 A: Schematic of pre-exposure contextual fear conditioning paradigm. B, C: Freezing across time (B) and
622 average freezing (C) during contextual fear conditioning for WT and Δ CTD GluA1 mice. Foot shocks are
623 indicated with vertical red dashed lines. Horizontal dashed line indicates baseline freezing (percentage
624 of time spent freezing during the 5 min. prior to the first shock). D, E: Freezing % across time (D) and
625 average freezing % (E) during context recall test for WT and Δ CTD GluA1 mice. Error bars represent
626 SEM. Empty dots represent females, filled dots represent males. n.s., not statistically different; **,
627 $p \leq 0.01$. B, D: two-way ANOVA. C: Mann-Whitney test. E: Welch's t-test.

628

629 **Figure 4. Δ CTD GluA1 mice recapitulate additional behavioral features of germline GluA1 knockout**
630 **mice.**

631 A: Schematic of elevated plus maze. B-D: Mean percentage of time spent in open arms (B), total
632 number of entries into the open arms (C) and total number of entries into the closed arms (D) for WT
633 and Δ CTD GluA1 mice. E: Schematic of light/dark box paradigm. F: Mean latency to enter the dark
634 compartment for WT and Δ CTD GluA1. G: Schematic of forced swim test. H: Mean time spent immobile
635 for WT and Δ CTD GluA1 mice. Error bars represent SEM. Empty dots represent females, filled dots

636 represent males. n.s., not statistically different; *, $p \leq 0.05$; ***, $p \leq 0.001$; ****, $p \leq 0.0001$. B, C, F: Mann-
637 Whitney test. D, H: Welch's t test.

638

639 **Figure 5. Exacerbated DG GC activation in Δ CTD GluA1 mice following open field exposure.**

640 A: Schematic of open field experiment. c-Fos expression was analyzed in several brain regions after two
641 hours in the open field arena in WT and Δ CTD GluA1 mice. B: representative c-Fos staining (red) in WT
642 and Δ CTD GluA1 hippocampus. C-E: Average number of c-Fos-positive cells in the dentate gyrus
643 granule layer, CA₃, and CA₁, respectively. Error bars represent SEM. Empty dots represent females,
644 filled dots represent males. Scale bar: 200 μ m. **, $p \leq 0.01$; ***, $p \leq 0.001$; ****, $p \leq 0.0001$, one-way
645 ANOVA.

646

647 **Figure 6. Intact excitatory synaptic transmission and LTP in DG granule cells but altered excitatory
648 synaptic transmission in DG inhibitory INs in Δ CTD GluA1 mice.**

649 A: Whole-cell patch-clamp recording set-up for slice electrophysiology experiments in DG granule cells
650 (GCs). B: Average paired-pulse ratio (PPR) values for evoked AMPAR EPSCs in WT and Δ CTD GluA1 GCs.
651 Representative WT (blue) and Δ CTD GluA1 (yellow) traces are shown to the right of the plot. C: Average
652 AMPAR/NMDAR ratios in WT and Δ CTD GluA1 GCs. D: Input-output relationship plot of AMPAR EPSCs
653 in WT and Δ CTD GluA1 DG GCs. Representative WT (blue) and Δ CTD GluA1 (yellow) traces are shown
654 to the right of the plot. E: AMPAR EPSC amplitude of WT and Δ CTD GluA1 DG GCs normalized to the
655 mean AMPAR EPSC amplitude before theta-burst LTP induction (arrow). Representative WT (blue) and
656 Δ CTD GluA1 (yellow) traces are shown to the right of the plot. n indicates number of cells induced /
657 number of cells at the end of the experiment (min. 40). F: Whole-cell patch-clamp recording set-up for
658 slice electrophysiology experiments in DG INs. WT and Δ CTD GluA1 mice were stereotaxically injected
659 (AAV-mDLX-GFP) to label INs in DG. G: Mean values of AMPAR/NMDAR ratios in WT and Δ CTD GluA1
660 mDLX-GFP(+)-labelled INs. Representative WT (blue) and Δ CTD GluA1 (yellow) traces are shown to the
661 right of the plot. Error bars represent SEM. Scale bars: 50pA, 20ms. n.s., not statistically different; *,
662 $p \leq 0.05$. B-C, E, G: unpaired t-test. D: two-way ANOVA.

663

664 **Suppl. Figure 1. Analysis of excitatory synapse density in CA1 and DG in WT and Δ CTD GluA1 mice.**

665 A-B: Average density of GluA1 and PSD-95 positive puncta in CA1 SR. C-D: Average density of GluA1
666 and PSD-95 positive puncta in DG ML. E-F: Average density of GluA2 and GluA3 positive puncta in CA1

667 SR. G-H: Average density of GluA2 and GluA3 positive puncta in DG ML. Error bars represent SEM. n.s.,
668 non-statistically significant; *, $p \leq 0.05$, unpaired t-test.

669

670 **Suppl. Figure 2. Control behavioral assessments in WT and Δ CTD GluA1 mice (related to Fig. 2).**

671 A-C: Average thigmotaxis (A), fine movements (B), and rearings (C) of WT and Δ CTD GluA1 male mice
672 during an open field test. D: Total distance travelled of WT, heterozygous, and homozygous Δ CTD
673 GluA1 female and male mice in the open field test. E-F: Mean distance traveled during training (E) and
674 test (F) for WT and CTD GluA1 mice in the OLM task. G-H: Mean object exploration time during training
675 (G) and test (H) for WT and CTD GluA1 mice in the OLM task. I-J: Mean distance traveled during training
676 (I) and test (J) for WT and CTD GluA1 mice in NOR task. K-L: Mean object exploration time during
677 training (K) and test (L) for WT and CTD GluA1 mice in NOR task. M: Linear regression of total distance
678 traveled (meters) and discrimination index during OLM test day. N: Linear regression of total object
679 exploration (seconds) and discrimination index during OLM test day. O: Average hind paw withdrawal
680 latency of WT and CTD GluA1 mice in the hot plate test. P: Average motion index of WT and Δ CTD
681 GluA1 mice during contextual fear conditioning (arbitrary units). Q: Linear regression of percentage of
682 freezing during conditioning (10 min) and recall (8 min). R: Average percentage of freezing measured
683 across time (minutes) during the fear generalization test for WT and Δ CTD GluA1 mice. S: Average
684 percentage of freezing during the fear generalization test for WT and Δ CTD GluA1 mice. Error bars
685 represent SEM. Empty dots represent females, filled dots represent males. n.s. not statistically different,
686 * $p \leq 0.05$, *** $p \leq 0.001$. A, B, H, O, S: Welch's t test. C, I, J, K: Mann-Whitney test. D: one-way ANOVA. E-
687 G, L: unpaired t-test. M, N, Q: Linear regression. P: multiple t design. R: two-way ANOVA.

688

689 **Suppl. Figure 3. Shock reactivity of WT and Δ CTD GluA1 mice in contextual fear conditioning**
690 **paradigm.**

691 Average motion index of WT and Δ CTD GluA1 mice during contextual fear conditioning (arbitrary units).
692 Error bars represent SEM. Empty dots represent females, filled dots represent males. Non-statistically
693 significant differences, two-way ANOVA.

694

695 **Suppl. Figure 4. Control behavioral assessments in WT and Δ CTD GluA1 mice (related to Fig. 4).**

696 A: Average time spent in the open arms across time during the elevated plus maze for WT and Δ CTD
697 GluA1 mice. B: Ratio of distance traveled in open arms relative to total distance traveled during the
698 elevated plus maze for WT and Δ CTD GluA1 mice. C: Average distance traveled in the closed arms

699 during the elevated plus maze for WT and Δ CTD GluA1 mice. D: Average total distance traveled during
700 the elevated plus maze for WT and Δ CTD GluA1 mice. E: Average time spent in the light zone of the
701 light/dark alternation test for WT and Δ CTD GluA1 mice. F: Average latency to immobility during the
702 forced swim test for WT and Δ CTD GluA1 mice. Error bars represent SEM. Empty dots represent
703 females, filled dots represent males. n.s., non-statistically significant; **, $p \leq 0.01$, ****, $p \leq 0.0001$, A:
704 two-way ANOVA. B-D: Welch's t-test. E: Mann-Whitney test. F: unpaired t-test.

705

706 **Suppl Figure 5. c-Fos analysis in various brain regions of WT and Δ CTD GluA1 mice following open**
707 **field exposure.**

708 A: Schematic of experimental timeline. B: c-Fos staining (red) of representative WT and Δ CTD GluA1
709 mouse brains showing habenula, somatosensory cortex, subthalamic nucleus, and amygdala. C: c-Fos
710 staining (red) of representative WT and Δ CTD GluA1 mouse brains showing prefrontal cortex. D: c-Fos
711 staining (red) of representative WT and Δ CTD GluA1 mouse brains showing motor cortex, striatum, and
712 nucleus accumbens. Error bars represent SEM. Error bars represent SEM. Empty dots represent females,
713 filled dots represent males. n.s., not statistically different; *, $p \leq 0.05$; **, $p \leq 0.01$; ***, $p \leq 0.001$; ****,
714 $p \leq 0.0001$, unpaired t-test, one-way ANOVA.

715

716

717

718 **References**

719 Aitta-Aho, T., M. Maksimovic, K. Dahl, R. Sprengel and E. R. Korpi (2019). "Attenuation of Novelty-
720 Induced Hyperactivity of Gria1-/- Mice by Cannabidiol and Hippocampal Inhibitory Chemogenetics."
721 Front Pharmacol **10**: 309.

722

723 Akgul, G. and C. J. McBain (2016). "Diverse roles for ionotropic glutamate receptors on inhibitory
724 interneurons in developing and adult brain." J Physiol **594**(19): 5471-5490.

725

726 Ancona Esselmann, S. G., J. Diaz-Alonso, J. M. Levy, M. A. Bemben and R. A. Nicoll (2017). "Synaptic
727 homeostasis requires the membrane-proximal carboxy tail of GluA2." Proc Natl Acad Sci U S A **114**(50):
728 13266-13271.

729

730 Bannerman, D. M., T. Borchardt, V. Jensen, A. Rozov, N. N. Haj-Yasein, N. Burnashev, D. Zamanillo, T.
731 Bus, I. Grube, G. Adelman, J. N. P. Rawlins and R. Sprengel (2018). "Somatic Accumulation of GluA1-
732 AMPA Receptors Leads to Selective Cognitive Impairments in Mice." Front Mol Neurosci **11**: 199.

733

734 Bannerman, D. M., R. M. Deacon, S. Brady, A. Bruce, R. Sprengel, P. H. Seeburg and J. N. Rawlins
735 (2004). "A comparison of GluR-A-deficient and wild-type mice on a test battery assessing sensorimotor,
736 affective, and cognitive behaviors." Behav Neurosci **118**(3): 643-647.

737
738 Barkus, C., M. Feyder, C. Graybeal, T. Wright, L. Wiedholz, A. Izquierdo, C. Kiselycznyk, W. Schmitt, D. J.
739 Sanderson, J. N. Rawlins, L. M. Saksida, T. J. Bussey, R. Sprengel, D.
740
741 Bannerman and A. Holmes (2012). "Do GluA1 knockout mice exhibit behavioral abnormalities relevant
742 to the negative or cognitive symptoms of schizophrenia and schizoaffective disorder?"
743 Neuropharmacology **62**(3): 1263-1272.
744
745 Barkus, C., D. J. Sanderson, J. N. Rawlins, M. E. Walton, P. J. Harrison and D. M. Bannerman (2014).
746 "What causes aberrant salience in schizophrenia? A role for impaired short-term habituation and the
747 GRIA1 (GluA1) AMPA receptor subunit." Mol Psychiatry **19**(10): 1060-1070.
748
749 Barria, A. M., D.; Derkach, V.; Griffith, L. C.; Soderling, T. R. (1997). "Regulatory Phosphorylation of
750 AMPA-Type Glutamate Receptors by CaM-KII During Long-Term Potentiation." Science **276**.
751
752 Bembem, M. A., M. Sandoval, A. A. Le, S. Won, V. N. Chau, J. C. Lauterborn, S. Incontro, K. H. Li, A. L.
753 Burlingame, K. W. Roche, C. M. Gall, R. A. Nicoll and J. Diaz-Alonso (2023). "Contrasting synaptic roles
754 of MDGA1 and MDGA2." bioRxiv.
755
756 Bernard, C., D. Exposito-Alonso, M. Selten, S. Sanalidou, A. Hanusz-Godoy, A. Aguilera, F. Hamid, F.
757 Oozeer, P. Maeso, L. Allison, M. Russell, R. A. Fleck, B. Rico and O. Marin (2022). "Cortical wiring by
758 synapse type-specific control of local protein synthesis." Science **378**(6622): eabm7466.
759
760 Bessa-Neto, D. and D. Choquet (2023). "Molecular mechanisms of AMPAR reversible stabilization at
761 synapses." Mol Cell Neurosci **125**: 103856.
762
763 Boehm, J., M. G. Kang, R. C. Johnson, J. Esteban, R. L. Huganir and R. Malinow (2006). "Synaptic
764 incorporation of AMPA receptors during LTP is controlled by a PKC phosphorylation site on GluR1."
765 Neuron **51**(2): 213-225.
766
767 Bonnet, C., J. Charpentier, N. Retailleau, D. Choquet and F. Coussen (2023). "Regulation of different
768 phases of AMPA receptor intracellular transport by 4.1N and SAP97." Elife **12**.
769
770 Bygrave, A. M., T. Jahans-Price, A. R. Wolff, R. Sprengel, D. M. Kullmann, D. M. Bannerman and D.
771 Katzel (2019). "Hippocampal-prefrontal coherence mediates working memory and selective attention
772 at distinct frequency bands and provides a causal link between schizophrenia and its risk gene GRIA1."
773 Transl Psychiatry **9**(1): 142.
774
775 Can, A., D. T. Dao, M. Arad, C. E. Terrillion, S. C. Piantadosi and T. D. Gould (2012). "The mouse forced
776 swim test." J Vis Exp(59): e3638.
777
778 Chen-Engerer, H. J., S. Jaeger, R. Bondarenko, R. Sprengel, B. Hengerer, H. Rosenbrock, V. Mack and N.
779 Schuelert (2022). "Increasing the Excitatory Drive Rescues Excitatory/Inhibitory Imbalance and
780 Mismatch Negativity Deficit Caused by Parvalbumin Specific GluA1 Deletion." Neuroscience **496**: 190-
781 204.
782
783 Collingridge, G. L., J. T. Isaac and Y. T. Wang (2004). "Receptor trafficking and synaptic plasticity." Nat
784 Rev Neurosci **5**(12): 952-962.

785
786 Coyle, J. T. (2006). "Glutamate and schizophrenia: beyond the dopamine hypothesis." Cell Mol
787 Neurobiol **26**(4-6): 365-384.
788
789 Curley, A. A. and D. A. Lewis (2012). "Cortical basket cell dysfunction in schizophrenia." J Physiol **590**(4):
790 715-724.
791
792 Del Pino, I., C. Garcia-Frigola, N. Dehorter, J. R. Brotons-Mas, E. Alvarez-Salvado, M. Martinez de
793 Lagran, G. Ciceri, M. V. Gabaldon, D. Moratal, M. Dierssen, S. Canals, O. Marin and B. Rico (2013).
794 "ErbB4 deletion from fast-spiking interneurons causes schizophrenia-like phenotypes." Neuron **79**(6):
795 1152-1168.
796
797 Diaz-Alonso, J., W. Morishita, S. Incontro, J. Simms, J. Holtzman, M. Gill, L. Mucke, R. C. Malenka and R.
798 A. Nicoll (2020). "Long-term potentiation is independent of the C-tail of the GluA1 AMPA receptor
799 subunit." Elife **9**.
800
801 Diaz-Alonso, J. and R. A. Nicoll (2021). "AMPA receptor trafficking and LTP: Carboxy-termini, amino-
802 termini and TARPs." Neuropharmacology **197**: 108710.
803
804 Diaz-Alonso, J., Y. J. Sun, A. J. Granger, J. M. Levy, S. M. Blankenship and R. A. Nicoll (2017). "Subunit-
805 specific role for the amino-terminal domain of AMPA receptors in synaptic targeting." Proc Natl Acad
806 Sci U S A **114**(27): 7136-7141.
807
808 Diering, G. H., S. Heo, N. K. Hussain, B. Liu and R. L. Huganir (2016). "Extensive phosphorylation of
809 AMPA receptors in neurons." Proc Natl Acad Sci U S A **113**(33): E4920-4927.
810
811 Diering, G. H. and R. L. Huganir (2018). "The AMPA Receptor Code of Synaptic Plasticity." Neuron
812 **100**(2): 314-329.
813
814 Dimidschstein, J., Q. Chen, R. Tremblay, S. L. Rogers, G. A. Saldi, L. Guo, Q. Xu, R. Liu, C. Lu, J. Chu, J. S.
815 Grimley, A. R. Krostag, A. Kaykas, M. C. Avery, M. S. Rashid, M. Baek, A. L. Jacob, G. B. Smith, D. E.
816 Wilson, G. Kosche, I. Kruglikov, T. Rusielewicz, V. C. Kotak, T. M. Mowery, S. A. Anderson, E. M.
817 Callaway, J. S. Dasen, D. Fitzpatrick, V. Fossati, M. A. Long, S. Noggle, J. H. Reynolds, D. H. Sanes, B.
818 Rudy, G. Feng and G. Fishell (2016). "A viral strategy for targeting and manipulating interneurons across
819 vertebrate species." Nat Neurosci **19**(12): 1743-1749.
820
821 Eastwood, S. L. K. R. W. H., P. J. (1996). "Immunoautoradiographic Evidence for a Loss of α -Amino-3-
822 Hydroxy-5-Methyl-4-Isloxazole Propionate- Preferring non-N-Methyl-D-Aspartate Glutamate Receptors
823 within the Medial Temporal Lobe in Schizophrenia." Biological Psychiatry **41**: 636-643.
824
825 Espinoza, C., S. J. Guzman, X. Zhang and P. Jonas (2018). "Parvalbumin(+) interneurons obey unique
826 connectivity rules and establish a powerful lateral-inhibition microcircuit in dentate gyrus." Nat
827 Commun **9**(1): 4605.
828
829 Esteban, J. A., S. H. Shi, C. Wilson, M. Nuriya, R. L. Huganir and R. Malinow (2003). "PKA
830 phosphorylation of AMPA receptor subunits controls synaptic trafficking underlying plasticity." Nat
831 Neurosci **6**(2): 136-143.
832


- 833 Fitzgerald, P. J., C. Barkus, M. Feyder, L. M. Wiedholz, Y. C. Chen, R. M. Karlsson, R. Machado-Vieira, C.
834 Graybeal, T. Sharp, C. Zarate, J. Harvey-White, J. Du, R. Sprengel, P. Gass, D. Bannerman and A.
835 Holmes (2010). "Does gene deletion of AMPA GluA1 phenocopy features of schizoaffective disorder?"
836 Neurobiol Dis **40**(3): 608-621.
- 837
838 Fuchs, E. C., A. R. Zivkovic, M. O. Cunningham, S. Middleton, F. E. Lebeau, D. M. Bannerman, A. Rozov,
839 M. A. Whittington, R. D. Traub, J. N. Rawlins and H. Monyer (2007). "Recruitment of parvalbumin-
840 positive interneurons determines hippocampal function and associated behavior." Neuron **53**(4): 591-
841 604.
- 842
843 Gainey, M. A., J. R. Hurvitz-Wolff, M. E. Lambo and G. G. Turrigiano (2009). "Synaptic scaling requires
844 the GluR2 subunit of the AMPA receptor." J Neurosci **29**(20): 6479-6489.
- 845
846 Gall, C. M., A. A. Le and G. Lynch (2024). "Contributions of site- and sex-specific LTPs to everyday
847 memory." Philos Trans R Soc Lond B Biol Sci **379**(1906): 20230223.
- 848
849 Granger, A. J., Y. Shi, W. Lu, M. Cerpas and R. A. Nicoll (2013). "LTP requires a reserve pool of
850 glutamate receptors independent of subunit type." Nature **493**(7433): 495-500.
- 851
852 Hansen, K. B., L. P. Wollmuth, D. Bowie, H. Furukawa, F. S. Menniti, A. I. Sobolevsky, G. T. Swanson, S.
853 A. Swanger, I. H. Greger, T. Nakagawa, C. J. McBain, V. Jayaraman, C. M. Low, M. L. Dell'Acqua, J. S.
854 Diamond, C. R. Camp, R. E. Perszyk, H. Yuan and S. F. Traynelis (2021). "Structure, Function, and
855 Pharmacology of Glutamate Receptor Ion Channels." Pharmacol Rev **73**(4): 298-487.
- 856
857 Harrison, P. J. M., D.; Kerwin, R.W. (1991). "Decreased hippocampal expression of a glutamate receptor
858 gene in schizophrenia." Lancet **337**: 450-452.
- 859
860 Hayashi, Y., S. H. Shi, J. A. Esteban, A. Piccini, J. C. Poncer and R. Malinow (2000). "Driving AMPA
861 receptors into synapses by LTP and CaMKII: requirement for GluR1 and PDZ domain interaction."
862 Science **287**(5461): 2262-2267.
- 863
864 Hosokawa, T., D. Mitsushima, R. Kaneko and Y. Hayashi (2015). "Stoichiometry and phosphoisotypes of
865 hippocampal AMPA-type glutamate receptor phosphorylation." Neuron **85**(1): 60-67.
- 866
867 Humeau, Y., D. Reisel, A. W. Johnson, T. Borchardt, V. Jensen, C. Gebhardt, V. Bosch, P. Gass, D. M.
868 Bannerman, M. A. Good, O. Hvalby, R. Sprengel and A. Luthi (2007). "A pathway-specific function for
869 different AMPA receptor subunits in amygdala long-term potentiation and fear conditioning." J
870 Neurosci **27**(41): 10947-10956.
- 871
872 Ismail, V., L. G. Zachariassen, A. Godwin, M. Sahakian, S. Ellard, K. L. Stals, E. Baple, K. T. Brown, N.
873 Foulds, G. Whewey, M. O. Parker, S. M. Lyngby, M. G. Pedersen, J. Desir, A. Bayat, M. Musgaard, M.
874 Guille, A. S. Kristensen and D. Baralle (2022). "Identification and functional evaluation of GRIA1
875 missense and truncation variants in individuals with ID: An emerging neurodevelopmental syndrome."
876 Am J Hum Genet **109**(7): 1217-1241.
- 877
878 Jensen, V., K. M. Kaiser, T. Borchardt, G. Adelman, A. Rozov, N. Burnashev, C. Brix, M. Frotscher, P.
879 Andersen, O. Hvalby, B. Sakmann, P. H. Seeburg and R. Sprengel (2003). "A juvenile form of





- 880 postsynaptic hippocampal long-term potentiation in mice deficient for the AMPA receptor subunit
881 GluR-A." J Physiol **553**(Pt 3): 843-856.
- 882
- 883 Kauer, J. A., R. C. Malenka and R. A. Nicoll (1988). "A persistent postsynaptic modification mediates
884 long-term potentiation in the hippocampus." Neuron **1**(10): 911-917.
- 885
- 886 Kay, Y., L. Tsan, E. A. Davis, C. Tian, L. Decarie-Spain, A. Sadybekov, A. N. Pushkin, V. Katritch, S. E.
887 Kanoski and B. E. Herring (2022). "Schizophrenia-associated SAP97 mutations increase glutamatergic
888 synapse strength in the dentate gyrus and impair contextual episodic memory in rats." Nat Commun
889 **13**(1): 798.
- 890
- 891 Kerr, J. M. and T. A. Blanpied (2012). "Subsynaptic AMPA receptor distribution is acutely regulated by
892 actin-driven reorganization of the postsynaptic density." J Neurosci **32**(2): 658-673.
- 893
- 894 Kim, C. H., K. Takamiya, R. S. Petralia, R. Sattler, S. Yu, W. Zhou, R. Kalb, R. Wenthold and R. Huganir
895 (2005). "Persistent hippocampal CA1 LTP in mice lacking the C-terminal PDZ ligand of GluR1." Nat
896 Neurosci **8**(8): 985-987.
- 897
- 898 Lee, H. K., K. Takamiya, J. S. Han, H. Man, C. H. Kim, G. Rumbaugh, S. Yu, L. Ding, C. He, R. S. Petralia,
899 R. J. Wenthold, M. Gallagher and R. L. Huganir (2003). "Phosphorylation of the AMPA receptor GluR1
900 subunit is required for synaptic plasticity and retention of spatial memory." Cell **112**(5): 631-643.
- 901
- 902 Lisman, J. E., J. T. Coyle, R. W. Green, D. C. Javitt, F. M. Benes, S. Heckers and A. A. Grace (2008).
903 "Circuit-based framework for understanding neurotransmitter and risk gene interactions in
904 schizophrenia." Trends Neurosci **31**(5): 234-242.
- 905
- 906 Lu, W., Y. Shi, A. C. Jackson, K. Bjorgan, M. J. During, R. Sprengel, P. H. Seeburg and R. A. Nicoll (2009).
907 "Subunit composition of synaptic AMPA receptors revealed by a single-cell genetic approach." Neuron
908 **62**(2): 254-268.
- 909
- 910 Luchkina, N. V., S. K. Coleman, J. Huupponen, C. Cai, A. Kivisto, T. Taira, K. Keinanen and S. E. Lauri
911 (2017). "Molecular mechanisms controlling synaptic recruitment of GluA4 subunit-containing AMPA-
912 receptors critical for functional maturation of CA1 glutamatergic synapses." Neuropharmacology
913 **112**(Pt A): 46-56.
- 914
- 915 Malinow, R. and R. C. Malenka (2002). "AMPA receptor trafficking and synaptic plasticity." Annu Rev
916 Neurosci **25**: 103-126.
- 917
- 918 Marin, O. (2012). "Interneuron dysfunction in psychiatric disorders." Nat Rev Neurosci **13**(2): 107-120.
- 919
- 920 Martin, S. J., P. D. Grimwood and R. G. Morris (2000). "Synaptic plasticity and memory: an evaluation of
921 the hypothesis." Annu Rev Neurosci **23**: 649-711.
- 922
- 923 Muller, D., M. Joly and G. Lynch (1988). "Contributions of quisqualate and NMDA receptors to the
924 induction and expression of LTP." Science **242**(4886): 1694-1697.
- 925
- 926 Nicoll, R. A. (2017). "A Brief History of Long-Term Potentiation." Neuron **93**(2): 281-290.
- 927

- 928 Panayi, M. C., T. Boerner, T. Jahans-Price, A. Huber, R. Sprengel, G. Gilmour, D. J. Sanderson, P. J.
929 Harrison, M. E. Walton and D. M. Bannerman (2023). "Glutamatergic dysfunction leads to a hyper-
930 dopaminergic phenotype through deficits in short-term habituation: a mechanism for aberrant
931 salience." *Mol Psychiatry* **28**(2): 579-587.
- 932
933 Pelkey, K. A., R. Chittajallu, M. T. Craig, L. Tricoire, J. C. Wester and C. J. McBain (2017). "Hippocampal
934 GABAergic Inhibitory Interneurons." *Physiol Rev* **97**(4): 1619-1747.
- 935
936 Procaccini, C., T. Aitta-aho, K. Jaako-Movits, A. Zharkovsky, A. Panhelainen, R. Sprengel, A. M. Linden
937 and E. R. Korpi (2011). "Excessive novelty-induced c-Fos expression and altered neurogenesis in the
938 hippocampus of GluA1 knockout mice." *Eur J Neurosci* **33**(1): 161-174.
- 939
940 Reisel, D., D. M. Bannerman, W. B. Schmitt, R. M. Deacon, J. Flint, T. Borchardt, P. H. Seeburg and J. N.
941 Rawlins (2002). "Spatial memory dissociations in mice lacking GluR1." *Nat Neurosci* **5**(9): 868-873.
- 942
943 Ripke, S., C. O'Dushlaine, K. Chambert, J. L. Moran, A. K. Kahler, S. Akterin, S. E. Bergen, A. L. Collins, J.
944 J. Crowley, M. Fromer, Y. Kim, S. H. Lee, P. K. Magnusson, N. Sanchez, E. A. Stahl, S. Williams, N. R.
945 Wray, K. Xia, F. Bettella, A. D. Borglum, B. K. Bulik-Sullivan, P. Cormican, N. Craddock, C. de Leeuw, N.
946 Durmishi, M. Gill, V. Golimbet, M. L. Hamshere, P. Holmans, D. M. Hougaard, K. S. Kendler, K. Lin, D. W.
947 Morris, O. Mors, P. B. Mortensen, B. M. Neale, F. A. O'Neill, M. J. Owen, M. P. Milovancevic, D.
948 Posthuma, J. Powell, A. L. Richards, B. P. Riley, D. Ruderfer, D. Rujescu, E. Sigurdsson, T. Silagadze, A.
949 B. Smit, H. Stefansson, S. Steinberg, J. Suvisaari, S. Tosato, M. Verhage, J. T. Walters, C. Multicenter
950 Genetic Studies of Schizophrenia, D. F. Levinson, P. V. Gejman, K. S. Kendler, C. Laurent, B. J. Mowry,
951 M. C. O'Donovan, M. J. Owen, A. E. Pulver, B. P. Riley, S. G. Schwab, D. B. Wildenauer, F. Dudbridge, P.
952 Holmans, J. Shi, M. Albus, M. Alexander, D. Champion, D. Cohen, D. Dikeos, J. Duan, P. Eichhammer, S.
953 Godard, M. Hansen, F. B. Lerer, K. Y. Liang, W. Maier, J. Mallet, D. A. Nertney, G. Nestadt, N. Norton, F.
954 A. O'Neill, G. N. Papadimitriou, R. Ribble, A. R. Sanders, J. M. Silverman, D. Walsh, N. M. Williams, B.
955 Wormley, C. Psychosis Endophenotypes International, M. J. Arranz, S. Bakker, S. Bender, E. Bramon, D.
956 Collier, B. Crespo-Facorro, J. Hall, C. Iyegbe, A. Jablensky, R. S. Kahn, L. Kalaydjieva, S. Lawrie, C. M.
957 Lewis, K. Lin, D. H. Linszen, I. Mata, A. McIntosh, R. M. Murray, R. A. Ophoff, J. Powell, D. Rujescu, J.
958 Van Os, M. Walshe, M. Weisbrod, D. Wiersma, C. Wellcome Trust Case Control, P. Donnelly, I. Barroso,
959 J. M. Blackwell, E. Bramon, M. A. Brown, J. P. Casas, A. P. Corvin, P. Deloukas, A. Duncanson, J.
960 Jankowski, H. S. Markus, C. G. Mathew, C. N. Palmer, R. Plomin, A. Rautanen, S. J. Sawcer, R. C.
961 Trembath, A. C. Viswanathan, N. W. Wood, C. C. Spencer, G. Band, C. Bellenguez, C. Freeman, G.
962 Hellenthal, E. Giannoulatou, M. Pirinen, R. D. Pearson, A. Strange, Z. Su, D. Vukcevic, P. Donnelly, C.
963 Langford, S. E. Hunt, S. Edkins, R. Gwilliam, H. Blackburn, S. J. Bumpstead, S. Dronov, M. Gillman, E.
964 Gray, N. Hammond, A. Jayakumar, O. T. McCann, J. Liddle, S. C. Potter, R. Ravindrarajah, M. Ricketts,
965 A. Tashakkori-Ghanbaria, M. J. Waller, P. Weston, S. Widaa, P. Whittaker, I. Barroso, P. Deloukas, C. G.
966 Mathew, J. M. Blackwell, M. A. Brown, A. P. Corvin, M. I. McCarthy, C. C. Spencer, E. Bramon, A. P.
967 Corvin, M. C. O'Donovan, K. Stefansson, E. Scolnick, S. Purcell, S. A. McCarroll, P. Sklar, C. M. Hultman
968 and P. F. Sullivan (2013). "Genome-wide association analysis identifies 13 new risk loci for
969 schizophrenia." *Nat Genet* **45**(10): 1150-1159.
- 970
971 Ruden, J. B., L. L. Dugan and C. Konradi (2021). "Parvalbumin interneuron vulnerability and brain
972 disorders." *Neuropsychopharmacology* **46**(2): 279-287.
- 973
974 Sanderson, D. J., M. A. Good, K. Skelton, R. Sprengel, P. H. Seeburg, J. N. Rawlins and D. M.
975 Bannerman (2009). "Enhanced long-term and impaired short-term spatial memory in GluA1 AMPA


976 receptor subunit knockout mice: evidence for a dual-process memory model." *Learn Mem* **16**(6): 379-
977 386.
978
979 Sanderson, D. J., R. Sprengel, P. H. Seeburg and D. M. Bannerman (2011). "Deletion of the GluA1 AMPA
980 receptor subunit alters the expression of short-term memory." *Learn Mem* **18**(3): 128-131.
981
982 Sans, N., C. Racca, R. S. Petralia, Y. X. Wang, J. McCallum and R. J. Wenthold (2001). "Synapse-
983 associated protein 97 selectively associates with a subset of AMPA receptors early in their biosynthetic
984 pathway." *J Neurosci* **21**(19): 7506-7516.
985
986 Schizophrenia Working Group of the Psychiatric Genomics, C. (2014). "Biological insights from 108
987 schizophrenia-associated genetic loci." *Nature* **511**(7510): 421-427.
988
989 Schwenk, J., D. Baehrens, A. Haupt, W. Bildl, S. Boudkazi, J. Roeper, B. Fakler and U. Schulte (2014).
990 "Regional diversity and developmental dynamics of the AMPA-receptor proteome in the mammalian
991 brain." *Neuron* **84**(1): 41-54.
992
993 Shen, L., F. Liang, L. D. Walensky and R. L. Huganir (2000). "Regulation of AMPA receptor GluR1
994 subunit surface expression by a 4. 1N-linked actin cytoskeletal association." *J Neurosci* **20**(21): 7932-
995 7940.
996
997 Shi, S., Y. Hayashi, J. A. Esteban and R. Malinow (2001). "Subunit-specific rules governing AMPA
998 receptor trafficking to synapses in hippocampal pyramidal neurons." *Cell* **105**(3): 331-343.
999
1000 Stockwell, I., J. F. Watson and I. H. Greger (2024). "Tuning synaptic strength by regulation of AMPA
1001 glutamate receptor localization." *Bioessays*: e2400006.
1002
1003 Tamminga, C. A., S. Southcott, C. Sacco, A. D. Wagner and S. Ghose (2012). "Glutamate dysfunction in
1004 hippocampus: relevance of dentate gyrus and CA3 signaling." *Schizophr Bull* **38**(5): 927-935.
1005
1006 Traunmuller, L., A. M. Gomez, T. M. Nguyen and P. Scheiffele (2016). "Control of neuronal synapse
1007 specification by a highly dedicated alternative splicing program." *Science* **352**(6288): 982-986.
1008
1009 Vogel-Ciernia, A. and M. A. Wood (2014). "Examining object location and object recognition memory in
1010 mice." *Curr Protoc Neurosci* **69**: 8 31 31-17.
1011
1012 Watson, J. F., A. Pinggera, H. Ho and I. H. Greger (2021). "AMPA receptor anchoring at CA1 synapses is
1013 determined by N-terminal domain and TARP gamma8 interactions." *Nat Commun* **12**(1): 5083.
1014
1015 Yonezawa, K., H. Tani, S. Nakajima, N. Nagai, T. Koizumi, T. Miyazaki, M. Mimura, T. Takahashi and H.
1016 Uchida (2022). "AMPA receptors in schizophrenia: A systematic review of postmortem studies on
1017 receptor subunit expression and binding." *Schizophr Res* **243**: 98-109.
1018
1019 Zamanillo, D., R. Sprengel, O. Hvalby, V. Jensen, N. Burnashev, A. Rozov, K. M. Kaiser, H. J. Koster, T.
1020 Borchardt, P. Worley, J. Lubke, M. Frotscher, P. H. Kelly, B. Sommer, P. H. Seeburg and B.
1021 Sakmann (1999). "Importance of AMPA receptors for hippocampal synaptic plasticity but not for spatial
1022 learning." *Science* **284**(5421): 1805-1811.
1023

1024 Zamanillo D.; Sprengel, R. H., Ø.; Jensen, V.; Burnashev, N.; Rozov, A.; and K. M. M. K. Kaiser, H. J.;
1025 Borchardt, T.; Worley, P.; Lubke, J.; Frotscher, M.; Kelly, P. H.; Sommer, B.; Andersen, P.; Seeburg, P. H.;
1026 Sakmann, B. (1999). "Importance of AMPA Receptors for Hippocampal Synaptic Plasticity But Not for
1027 Spatial
1028 Learning." Science **284**.
1029







Elevated plus maze




Forced swim test




A




B




C







D



E








Object location memory test

Novel object recognition test



Contextual fear conditioning test

